Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $46.65 Consensus Target Price from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have earned an average rating of “Moderate Buy” from the nineteen analysts that are currently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $46.65.

APLS has been the topic of several recent research reports. Robert W. Baird lowered their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $25.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Bank of America decreased their target price on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Piper Sandler cut their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 6,247 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the transaction, the chief executive officer now owns 307,415 shares of the company’s stock, valued at approximately $8,822,810.50. This trade represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the sale, the chief financial officer now owns 88,100 shares in the company, valued at $2,528,470. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,308 shares of company stock valued at $511,406 in the last quarter. Corporate insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in APLS. Braidwell LP grew its stake in shares of Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after purchasing an additional 2,513,383 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Apellis Pharmaceuticals by 191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares during the last quarter. JPMorgan Chase & Co. raised its position in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after acquiring an additional 735,160 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at approximately $6,226,000. Finally, AQR Capital Management LLC lifted its position in shares of Apellis Pharmaceuticals by 337.3% in the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after acquiring an additional 190,420 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Trading Up 0.7 %

Shares of APLS stock opened at $29.93 on Wednesday. Apellis Pharmaceuticals has a fifty-two week low of $24.34 and a fifty-two week high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock’s fifty day moving average is $31.88 and its two-hundred day moving average is $33.35. The firm has a market capitalization of $3.72 billion, a P/E ratio of -14.74 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same period in the prior year, the business posted ($1.17) earnings per share. The business’s quarterly revenue was up 78.3% on a year-over-year basis. Research analysts expect that Apellis Pharmaceuticals will post -1.73 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).